Guilin Sanjin Pharmaceutical Co., Ltd.

002275

CNE100000DY9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
12.44 ^CNY	+1.22%		+0.81%	-14.15%

04-26	Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	CI
04-25	Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Guilin Sanjin Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 29, 2018.

January 02, 2019

From October 25, 2018 to December 31, 2018, the company has repurchased 1,877,759 shares, representing 0.32% for CNY 24.76 million. With this, the company has completed the repurchase of 1,877,759 shares, representing 0.32% for CNY 24.76 million under the buyback announced on October 29, 2018.

Latest news about Guilin Sanjin Pharmaceutical Co., Ltd.

Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	04-26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-04	CI
Guilin Sanjin Pharma to Sell Land, Buildings For 111 Million Yuan	12-28	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Implements Profit Distribution plan for the Third Quarter of 2023, Payable on 27 November 2023	11-21	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves 2023 Third Quarter Profit Distribution Plan	11-15	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Third Quarter Dividend for 2023	23-10-30	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Guilin Sanjin Pharmaceutical Co., Ltd.(XSEC:002275) added to S&P Global BMI Index	23-09-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 31, 2023	23-05-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022	23-05-22	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Board Elections	22-12-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Dividend for the Third Quarter of 2022	22-11-15	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Third Quarter of 2022	22-10-31	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO	22-08-31	MT
Biocytogen Pharmaceuticals Launches $70 Million Hong Kong IPO	22-08-19	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on 30 May 2022	22-05-24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	22-05-19	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021	22-04-27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

Duration

Period

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

More charts

Company Profile

Guilin Sanjin Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research, production and distribution of Chinese patent medicines, as well as distribution of products. The Company's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. It distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
GUILIN SANJIN PHARMACEUTICAL CO., LTD.	-14.15%	994M
DONG-E-E-JIAO CO.,LTD.	+7.30%	4.81B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-31.08%	3.6B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	3.09B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.32%	2.62B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.35%	2.27B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+34.19%	1.82B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.49%	1.41B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-15.07%	1.38B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+40.95%	1.37B

Alternative Medicine

Guilin Sanjin Pharmaceutical Co., Ltd.

Equities

002275

CNE100000DY9

Pharmaceuticals

Tranche Update on Guilin Sanjin Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 29, 2018.

Latest news about Guilin Sanjin Pharmaceutical Co., Ltd.

Chart Guilin Sanjin Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Alternative Medicine